CD20-directed Antibody Interactions

Name
CD20-directed Antibody Interactions
Accession Number
DBCAT004203
Description

Not Available

Drugs
DrugDrug Description
RituximabA monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
Ibritumomab tiuxetanA monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
TositumomabA monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
OfatumumabAn anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.
ObinutuzumabAn antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
OcrelizumabA CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis.
Drugs & Drug Targets
DrugTargetType
RituximabB-lymphocyte antigen CD20target
Ibritumomab tiuxetanB-lymphocyte antigen CD20target
TositumomabB-lymphocyte antigen CD20target
TositumomabLow affinity immunoglobulin gamma Fc region receptor II-btarget
OfatumumabB-lymphocyte antigen CD20target
ObinutuzumabB-lymphocyte antigen CD20target
OcrelizumabB-lymphocyte antigen CD20target